482
Views
7
CrossRef citations to date
0
Altmetric
Clinical Study

Predictive Factors of Clinical Outcome in Patients with Diffuse Proliferative Lupus Nephritis Treated Early by Intravenous Methylprednisolone Pulse Therapy

, , &
Pages 41-47 | Published online: 07 Jul 2009

REFERENCES

  • Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413–424
  • Baqi N, Moozami S, Singh A, Ahmad H, Bahlachandra S, Tejani A. Lupus nephritis in children: A longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996; 7: 924–929
  • Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: Contribution of renal histologic data. Am J Med 1983; 74: 382–391
  • Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989; 36: 891–896
  • Lewis EJ, Hunsicker LG, Lan SP, Rhode RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1373–1379
  • Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121–2131
  • Austin HA, 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689–695
  • Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Q J Med 1989; 72: 779–833
  • Howie AJ, Turhan N, Adu D. Powerful morphometric indicator of prognosis in lupus nephritis. Q J Med 2003; 96: 411–420
  • Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int 1992; 42: 743–748
  • Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1993; 21: 374–377
  • Lim CS, Chin HJ, Jung YC, et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 1999; 52: 139–147
  • Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904–914
  • Weening JJ, D'Agati D, Schwartz M, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. Kidney Int 2004; 65: 521–530
  • Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904–914
  • Austin HA, Balow JE. Natural history and treatment of lupus nephritis. Semin Nephrol 1999; 19: 2–11
  • Chan TM, Tse KC, Tang CSO, Lai KN, Li FK. Long-term outcome of patients with DPLN treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265–272
  • Pollak VE, Pirani CL. Renal histologic findings in systemic lupus erythematosus. Mayo Clin Proc 1969; 44: 630–644
  • Contreras G, Tozman E, Nilay N, David M. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14: 33–38
  • Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophophamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248–257
  • Gourley MF, Austin HA, 3rd, Scott D, et al. Methylprednisolone and cyclophophamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549–557
  • Park MC, Park YB, Jung SY. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophophamide pulse therapy. Lupus 2004; 13: 569–574
  • Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004; 13: 366–371
  • Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34: 530–539
  • Austin HA, 3rd, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620–1628
  • Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognostic in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156–2163

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.